At week 26, the difference in HbA1c reduction from baseline between TRESIBA and insulin detemir was 0.15% with a 95% confidence interval of [-0.03%
What the Research Suggests Most of the existing evidence comes from preclinical (animal) studies
Understanding Semaglutide: What You Need to Know Semaglutide, a powerful tool for weight management in adults, is FDA-approved to help those struggling with obesity or weight-related conditions
Molestias digestivas (las ms comunes) Nuseas: entre 20% y 44% de los pacientes (ms comn al inicio y con dosis altas) Vmitos: entre 10% y 24% Diarrea: entre 12% y 30% Estreimiento: entre 6% y 24% , segn la molcula y la duracin En general, 4 a 7 de cada 10 pacientes (40-70%) presentan algn sntoma digestivo durante el tratamiento, sobre todo en las primeras semanas, con tendencia a mejorar con el tiempo (1,8-11)
(4) Haugland RB, Chang DT
Alcohol: Semaglutide mixed with alcohol may potentially affect the liver or cause hypoglycemia